nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

27.09.2023 | Research

Predicting cutaneous malignant melanoma patients’ survival using deep learning: a retrospective cohort study

verfasst von: Siyu Cai, Wei Li, Cong Deng, Qiao Tang, Zhou Zhou

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 19/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Cutaneous malignant melanoma (CMM) has the worst prognosis among skin cancers, especially metastatic CMM. Predicting its prognosis accurately could direct clinical decisions.

Methods

The Surveillance, Epidemiology, and End Results database was screened to collect CMM patients’ data. According to diagnosed time, patients were subdivided into three cohorts, train cohort (diagnosed between 2010 and 2013), validation cohort (diagnosed in 2014), and test cohort (diagnosed in 2015). Train cohort was used to train deep learning survival model for cutaneous malignant melanoma (DeepCMM). DeepCMM was then evaluated in train cohort and validation cohort internally, and validated in test cohort externally.

Results

DeepCMM showed 0.8270 (95% CI, confidence interval, CI 0.8260–0.8280) as area under the receiver operating characteristic curve (AUC) in train cohort, 0.8274 (95% CI 0.8286–0.8298) AUC in validation cohort, and 0.8303 (95% CI 0.8289–0.8316) AUC in test cohort. Then DeepCMM was packaged into a Windows 64-bit software for doctors to use.

Conclusion

Deep learning survival model for cutaneous malignant melanoma (DeepCMM) can offer a reliable prediction on cutaneous malignant melanoma patients’ overall survival.

Graphical abstract

Nur mit Berechtigung zugänglich

Abbas O, Miller DD, Bhawan J (2014) Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol 36(5):363–379. https://doi.org/10.1097/DAD.0b013e31828a2ec5CrossRefPubMed

Ali Z, Yousaf N, Larkin J (2013) Melanoma epidemiology, biology and prognosis. EJC Suppl 11(2):81–91. https://doi.org/10.1016/j.ejcsup.2013.07.012CrossRefPubMedPubMedCentral

Azzola MF, Shaw HM, Thompson JF, Soong S, Scolyer RA, Watson GF, Zhang Y (2003) Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 97:1488–1498 (reprinted)CrossRefPubMed

Balch CM, Gershenwald JE, Soong S, Thompson JF, Ding S, Byrd DR, Sondak VK (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459 (reprinted)CrossRefPubMedPubMedCentral

Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M (2005) The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 32(4):268–273CrossRefPubMed

Bonachela NL, Kowalski LP, Santos ABDO (2021) Risk factors for positive sentinel lymph nodes in head and neck melanoma - a survival analysis. Braz J Otorhinolaryngol 87(1):103–109. https://doi.org/10.1016/j.bjorl.2020.09.014CrossRefPubMed

Chen J, Yang H, Moi S, Chuang L, Yang C (2021) Identification of mortality-risk-related missense variant for renal clear cell carcinoma using deep learning. Ther Adv Chron Dis 12:1755284400. https://doi.org/10.1177/2040622321992624CrossRef

Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WER, Daud A, Urist MM (2012) Melanoma. J Natl Compr Cancer Netw JNCCN 10(3):366–400CrossRefPubMed

Cress RD, Holly EA (1997) Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988–93. Cancer Causes Control 8:246–252CrossRefPubMed

Danish HH, Patel KR, Switchenko JM, Gillespie TW, Jhaveri J, Chowdhary M, Khan MK (2016) The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 26(6):595–603CrossRefPubMedPubMedCentral

de Giorgi V, Rossari S, Gori A, Grazzini M, Savarese I, Crocetti E, Massi D (2012) The prognostic impact of the anatomical sites in the ‘head and neck melanoma’: scalp versus face and neck. Melanoma Res 22(5):402–405. https://doi.org/10.1097/CMR.0b013e3283577b96CrossRefPubMed

Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME (2016) The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol 40(12):e94–e102CrossRefPubMedPubMedCentral

Enninga EAL, Moser JC, Weaver AL, Markovic SN, Brewer JD, Leontovich AA, Dronca RS (2017) Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Med 6:2203–2212 (reprinted)CrossRefPubMedPubMedCentral

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Thompson JF (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Cancer J Clinicians 67(6):472–492. https://doi.org/10.3322/caac.21409CrossRef

Guy GPJ, Ekwueme DU, Tangka FK, Richardson LC (2012) Melanoma treatment costs: a systematic review of the literature, 1990–2011. Am J Prev Med 43(5):537–545. https://doi.org/10.1016/j.amepre.2012.07.031CrossRefPubMedPubMedCentral

Hathaway QA, Yanamala N, Budoff MJ, Sengupta PP, Zeb I (2021) Deep neural survival networks for cardiovascular risk prediction: the Multi-Ethnic Study of Atherosclerosis (MESA). Comput Biol Med 139:104983. https://doi.org/10.1016/j.compbiomed.2021.104983CrossRefPubMed

Hogue L, Harvey VM (2019) Basal cell carcinoma, squamous cell carcinoma, and cutaneous melanoma in skin of color patients. Dermatol Clin 37(4):519–526. https://doi.org/10.1016/j.det.2019.05.009CrossRefPubMed

Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y (2018) DeepSurv: personalized treatment recommender system using a Cox proportional hazards deep neural network. BMC Med Res Methodol 18(1):24. https://doi.org/10.1186/s12874-018-0482-1CrossRefPubMedPubMedCentral

Kim DW, Lee S, Kwon S, Nam W, Cha I, Kim HJ (2019) Deep learning-based survival prediction of oral cancer patients. Sci Rep 9(1):6994. https://doi.org/10.1038/s41598-019-43372-7CrossRefPubMedPubMedCentral

Košec A, Rašić I, Pegan A, Solter D, Ćurković M, Bedeković V (2021) Sex- and site-related significance in cutaneous head and neck melanoma. Ear Nose Throat J 100(5):343–349. https://doi.org/10.1177/0145561319875949CrossRefPubMed

Leonardi GC, Falzone L, Salemi R, Zanghì A, Spandidos DA, Mccubrey JA, Libra M (2018) Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol 52(4):1071–1080. https://doi.org/10.3892/ijo.2018.4287CrossRefPubMedPubMedCentral

Liu P, Zhu H, Zhu H, Zhang X, Feng A, Zhu X, Sun Y (2022) Predicting survival for hepatic arterial infusion chemotherapy of unresectable colorectal liver metastases: radiomics analysis of pretreatment computed tomography. J Transl Intern Med 10(1):56–64. https://doi.org/10.2478/jtim-2022-0004CrossRef

Moran B, Silva R, Perry AS, Gallagher WM (2018) Epigenetics of malignant melanoma. Semin Cancer Biol 51:80–88. https://doi.org/10.1016/j.semcancer.2017.10.006CrossRefPubMed

Rastrelli M, Tropea S, Rossi CR, Alaibac M (2014) Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo (athens, Greece) 28(6):1005–1011PubMed

Rockberg J, Amelio JM, Taylor A, Jörgensen L, Ragnhammar P, Hansson J (2016) Epidemiology of cutaneous melanoma in Sweden-stage-specific survival and rate of recurrence. Int J Cancer 139(12):2722–2729. https://doi.org/10.1002/ijc.30407CrossRefPubMed

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Ugurel S (2018) Melanoma. Lancet (london, England) 392(10151):971–984. https://doi.org/10.1016/S0140-6736(18)31559-9CrossRefPubMed

She Y, Jin Z, Wu J, Deng J, Zhang L, Su H, Chen C (2020) Development and validation of a deep learning model for non-small cell lung cancer survival. JAMA Netw Open 3:e205842 (reprinted)CrossRefPubMedPubMedCentral

Tseng WH, Martinez SR (2011) Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res 167(2):192–198. https://doi.org/10.1016/j.jss.2010.10.008CrossRefPubMed

Weiss SA, Hanniford D, Hernando E, Osman I (2015) Revisiting determinants of prognosis in cutaneous melanoma. Cancer 121(23):4108–4123. https://doi.org/10.1002/cncr.29634CrossRefPubMed

Xie J, Luo X, Deng X, Tang Y, Tian W, Cheng H, Xie X (2022) Advances in artificial intelligence to predict cancer immunotherapy efficacy. Front Immunol 13:1076883. https://doi.org/10.3389/fimmu.2022.1076883CrossRefPubMed

Xue J, Li J, Sun D, Sheng L, Gong Y, Wang D, Li Y (2022) Functional evaluation of intermediate coronary lesions with integrated computed tomography angiography and invasive angiography in patients with stable coronary artery disease. J Transl Intern Med 10(3):255–263. https://doi.org/10.2478/jtim-2022-0018CrossRef

Yu H, Huang T, Feng B, Lyu J (2022) Deep-learning model for predicting the survival of rectal adenocarcinoma patients based on a surveillance, epidemiology, and end results analysis. BMC Cancer 22(1):210. https://doi.org/10.1186/s12885-022-09217-9CrossRefPubMedPubMedCentral

Zhao J, Li D, Xie S, Deng X, Wen X, Li J, Ding Y (2022) Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: a Chinese population-based analysis. Front Immunol 13:1083840. https://doi.org/10.3389/fimmu.2022.1083840CrossRefPubMedPubMedCentral

Titel: Predicting cutaneous malignant melanoma patients’ survival using deep learning: a retrospective cohort study
verfasst von: Siyu Cai
Wei Li
Cong Deng
Qiao Tang
Zhou Zhou
Publikationsdatum: 27.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 19/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05421-7

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Predicting cutaneous malignant melanoma patients’ survival using deep learning: a retrospective cohort study

Abstract

Background

Methods

Results

Conclusion

Graphical abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Graphical abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 19/2023

CR5/CCL5 axis is linked to a poor outcome, and inhibition reduces metastasis in oral squamous cell carcinoma

Hematopoietic stem cells suppress proliferation and enhance differentiation of leukemia cells through regulating apoptotic and inflammatory genes

Personalized prognostic prediction tool for high-grade neuroendocrine cervical cancer: a SEER database analysis and single-center validation

Components of the JNK–MAPK pathway play distinct roles in hepatocellular carcinoma

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

Decoding the role of aberrant RNA alternative splicing in hepatocellular carcinoma: a comprehensive review

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie